218 related articles for article (PubMed ID: 32640933)
1. Tofacitinib, two-faced Janus in ulcerative colitis and Crohn's disease?
Biemans VB; Verstockt B
United European Gastroenterol J; 2020 Aug; 8(7):753-754. PubMed ID: 32640933
[No Abstract] [Full Text] [Related]
2. Exposure-response characterization of tofacitinib efficacy in moderate to severe ulcerative colitis: Results from a dose-ranging phase 2 trial.
Mukherjee A; Hazra A; Smith MK; Martin SW; Mould DR; Su C; Niezychowski W
Br J Clin Pharmacol; 2018 Jun; 84(6):1136-1145. PubMed ID: 29377257
[TBL] [Abstract][Full Text] [Related]
3. Real-World Experience with Tofacitinib in IBD at a Tertiary Center.
Weisshof R; Aharoni Golan M; Sossenheimer PH; El Jurdi K; Ollech JE; Pekow J; Cohen RD; Sakuraba A; Dalal S; Rubin DT
Dig Dis Sci; 2019 Jul; 64(7):1945-1951. PubMed ID: 30734234
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Infection Rates from the Ulcerative Colitis Clinical Programme.
Winthrop KL; Loftus EV; Baumgart DC; Reinisch W; Nduaka CI; Lawendy N; Chan G; Mundayat R; Friedman GS; Salese L; Thorpe AJ; Su C
J Crohns Colitis; 2021 Jun; 15(6):914-929. PubMed ID: 33245746
[TBL] [Abstract][Full Text] [Related]
5. Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multicentre UK Experience.
Honap S; Chee D; Chapman TP; Patel M; Kent AJ; Ray S; Sharma E; Kennedy J; Cripps S; Walsh A; Goodhand JR; Ahmad T; Satsangi J; Irving PM; Kennedy NA;
J Crohns Colitis; 2020 Oct; 14(10):1385-1393. PubMed ID: 32280965
[TBL] [Abstract][Full Text] [Related]
6. Adverse drug events associated with 5mg versus 10mg Tofacitinib (Janus kinase inhibitor) twice daily for the treatment of autoimmune diseases: A systematic review and meta-analysis of randomized controlled trials.
Huang F; Luo ZC
Clin Rheumatol; 2019 Feb; 38(2):523-534. PubMed ID: 30242639
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
Nader A; Stodtmann S; Friedel A; Mohamed MF; Othman AA
J Clin Pharmacol; 2020 Apr; 60(4):528-539. PubMed ID: 31701537
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology and safety of tofacitinib in ulcerative colitis.
López-Sanromán A; Esplugues JV; Domènech E
Gastroenterol Hepatol; 2021 Jan; 44(1):39-48. PubMed ID: 32829958
[TBL] [Abstract][Full Text] [Related]
9. Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program.
Lichtenstein GR; Rogler G; Ciorba MA; Su C; Chan G; Pedersen RD; Lawendy N; Quirk D; Nduaka CI; Thorpe AJ; Panés J
Inflamm Bowel Dis; 2021 May; 27(6):816-825. PubMed ID: 32766762
[TBL] [Abstract][Full Text] [Related]
10. Inhibitors of the Janus Kinases: A New Oral Treatment Option for Ulcerative Colitis.
Antonelli E; Torti G; Bassotti G
J Clin Gastroenterol; 2019 Oct; 53(9):635-640. PubMed ID: 31373941
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics of Tofacitinib in Patients With Moderate to Severe Ulcerative Colitis.
Vong C; Martin SW; Deng C; Xie R; Ito K; Su C; Sandborn WJ; Mukherjee A
Clin Pharmacol Drug Dev; 2021 Mar; 10(3):229-240. PubMed ID: 33513294
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Pregnancies With Maternal/Paternal Exposure in the Tofacitinib Safety Databases for Ulcerative Colitis.
Mahadevan U; Dubinsky MC; Su C; Lawendy N; Jones TV; Marren A; Zhang H; Graham D; Clowse MEB; Feldman SR; Baumgart DC
Inflamm Bowel Dis; 2018 Nov; 24(12):2494-2500. PubMed ID: 29982686
[TBL] [Abstract][Full Text] [Related]
13. Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers.
Krishnaswami S; Boy M; Chow V; Chan G
Clin Pharmacol Drug Dev; 2015 Mar; 4(2):83-8. PubMed ID: 27128212
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
[TBL] [Abstract][Full Text] [Related]
15. Short-term effectiveness and safety of tofacitinib in ulcerative colitis - real world data from tertiary medical centers in Israel.
Avni-Biron I; Bar-Gil Shitrit A; Koslowsky B; Levartovsky A; Kopylov U; Weisshof R; Aviv Cohen N; Maharshak N; Hovel D; Israeli E; Naftali T; Goren I; Snir Y; Ollech JE; Banai-Eran H; Broitman Y; Sharar-Fischler T; Dotan I; Yanai H
Dig Liver Dis; 2022 Feb; 54(2):192-197. PubMed ID: 34887214
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
Panés J; Sandborn WJ; Schreiber S; Sands BE; Vermeire S; D'Haens G; Panaccione R; Higgins PDR; Colombel JF; Feagan BG; Chan G; Moscariello M; Wang W; Niezychowski W; Marren A; Healey P; Maller E
Gut; 2017 Jun; 66(6):1049-1059. PubMed ID: 28209624
[TBL] [Abstract][Full Text] [Related]
17. Next generation of small molecules in inflammatory bowel disease.
Olivera P; Danese S; Peyrin-Biroulet L
Gut; 2017 Feb; 66(2):199-209. PubMed ID: 27856614
[No Abstract] [Full Text] [Related]
18. Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme.
Curtis JR; Lee EB; Kaplan IV; Kwok K; Geier J; Benda B; Soma K; Wang L; Riese R
Ann Rheum Dis; 2016 May; 75(5):831-41. PubMed ID: 25902789
[TBL] [Abstract][Full Text] [Related]
19. Effect of mizoribine in children with inflammatory bowel disease.
Fujii T; Ohtsuka Y; Yamakawa Y; Ohtani K; Kudo T; Ohtomo Y; Nagata S; Shimizu T
Pediatr Int; 2010 Feb; 52(1):e57-9. PubMed ID: 20158652
[No Abstract] [Full Text] [Related]
20. Janus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease.
Boland BS; Vermeire S
Gastroenterol Clin North Am; 2017 Sep; 46(3):627-644. PubMed ID: 28838419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
